Kevin Jang

Radiation Oncology Registrar | Clinical Lecturer @Sydney_Uni

[Kevin Jang @kevjang_]

My first book chapter arrived today. Thankful to have made a small contribution to this huge collaborative effort. @staartjesneuro @micnlab

[Kevin Jang @kevjang_]

Our latest study in @EditorNeuro demonstrates that dynamic FET-PET outperforms static metrics in distinguishing early recurrence from pseudoprogression in #GBM

@NeuroOnc @EANOassociation

https://t.co/LXfctReZD4

[Elio Adib @adib_elio]

Rewatching #BreakingBad in 2025 with fresh eyes as #Radonc resident☢️
Let's talk about how Walter White's Stage IIIA lung adenocarcinoma would be treated if diagnosed today instead of 2008. 🧵 #lcsm #MedTwitter
Because honestly? The show may look very different. Here's why...

[Felix Ehret @FelixEhretMD]

What’s the role of the extent of resection in grade 2 IDH-mutant glioma? I’m delighted to see this work published in @TheLancetOncol — thanks and congratulations to the team!

@NeuroOnc @EANOassociation @NSTumorSection @pkarschnia @jakeyoung11
https://t.co/CLwBvOTRyn

[Gerry Hanna @gerryhanna]

In this week’s @JAMAOnc - full published paper of a randomised trial of craniospinal vs involved field RT in treatment of leptomeningeal metastatic disease

➡️ PFS 8.2 vs 2.3 months, p<0.01

First trial that has really shifted the dial in this difficult clinical setting. #RadOnc

🔗 https://t.co/su8ABP9laA

[Norbert Galldiks @galldiks]

🧠 👉New clinical practice guideline in The Lancet Oncology. Out of the RANO group, we are proud to present our updated multidisciplinary, evidence-based guideline on PET imaging in patients with glioma.

https://t.co/rIe4t8leR0
🔗 #NeuroOncology #PETimaging #Glioma #RANO

[giuseppe Minniti @gminniti2012]

Here new recommendations for the use of PET imaging in patients with gliomas from RANO working group and the @EANOassociation
Update to the RANO working group and EANO recommendations for the clin... https://t.co/a73x5vIXpC
@SapienzaRoma
@galldiks

[giuseppe Minniti @gminniti2012]

Another dogma is disappearing: SRS is effective for SCLC BM.
Stereotactic Radiosurgery in Patients With Small Cell Lung Cancer and 1-10 Brain Metastases: A Multi-Institutional, Phase II, Prospective Clinical Trial | Journal of Clinical Oncology https://t.co/D08loaWWb3

[giuseppe Minniti @gminniti2012]

Congats to my residents Raffaella De Pietro and Lucy Zaccaro per this interesting review on #journalofneurooncology: The evolving role of reirradiation in the management of recurrent brain tumors https://t.co/dHNCkTqIAu

[ESTRO @ESTRO_RT]

Multi-Institutional Atlas of Brain Metastases Informs Spatial Modeling for Precision Imaging and Personalized Therapy, published in Nature Communications.
👉 Read it before your patients: https://t.co/EfQF5uvWl1
@NatureComms

[Kevin Jang @kevjang_]

Honoured to contribute to @BrainSci_MDPI Special Issue on “Advances in Neuro-Oncology”. Published just in time for Brain Tumour Awareness Month.

Full-text: https://t.co/khGgJ1KGrV

#GBM #DTI #Radiomics #Connectomics

[giuseppe Minniti @gminniti2012]

Another study supporting efficacy and safety of reirradiation... Many data indicate similar scenario for Primark brain tumors and metastasi.. waiting for @Legato_Horizon results on GBM reirradiation and lomustine vs lomustine alone
@EORTC
@SapienzaRoma
@EANOassociation

[Kevin Jang @kevjang_]

@gminniti2012 @Legato_Horizon @EORTC @SapienzaRoma @EANOassociation Thanks for sharing Prof Minniti. Keenly awaiting @Legato_Horizon

[Radiotherapy & Oncology @RO_GreenJournal]

🔥 Can SABR work twice?
Meta-analysis shows in-field #SABR reirradiation offers 78% 1-year control with low toxicity—especially for small tumours, high BED (≥200 Gy), &amp; long intervals.
💡 A safe, effective salvage option for recurrent #NSCLC.
📖 https://t.co/cyxuzGFvl9
#radonc

[Kevin Jang @kevjang_]

What about toxicity?
Pneumonitis ≥ Grade 2: 6.4%
Grade 3 events: rare
Grade 4–5 toxicity: only in central tumors
➡️ Peripheral lesions had excellent safety profiles.

Key takeaway: location matters for reirradiation safety.

[Kevin Jang @kevjang_]

Pleased to share our latest work in @RO_GreenJournal

In-field lung re-SABR achieves excellent outcomes with low toxicities.

Size, dose, timing matters. Best results seen in recurrent tumours &lt;2cm, cumulative BED ≥200 Gy, and interval &gt;12 months.

https://t.co/rbNWRazrMu

[Kevin Jang @kevjang_]

So what predicts better outcomes?

✅ Tumor size &lt;2 cm
✅ Cumulative BED ≥200 Gy
✅ Interval &gt;12 months between SABR courses

Size. Dose. Timing. All critically influence local control.

[Shankar Siva @_ShankarSiva]

📢🚨 Hot off the press @TheLancetOncol for #kidneycancer! https://t.co/v4fXO17tLp. SABR vs thermal ablation;
- Despite ⏫age, ⏬worse GFR, and ⏫tumours for SABR
- SABR ⬆️effective than TA (at 1, 2 and 5 yrs)
- esp for RCC &gt;4cm
- same renal decline (p=0.75)
- similar F/U #radonc

[Elliot Servais, MD, FACS @ElliotServaisMD]

Fellow lung cancer providers:
Who’s ready to try and memorize the 9th Ed staging which is now in place?!

Some notable changes:
-N2a &amp; N2b
-Not all N2 = stage III
-M1c1 &amp; M1c2

Ready or not…here it comes…